In April last year, the company and the University of Maryland entered into a license agreement covering specific antiviral compounds discovered by the university.
"Ultimately the goal is to have compounds that demonstrate strong antiviral activity against Influenza virus, SARS-CoV-2, and Ebolavirus," Alkido Pharma Chief Executive Anthony Hayes said.
The next step is to measure how well the compounds are bioavailable in the lungs when given either as an injection or as an oral dosing, according to a statement.
Price: 0.85, Change: -0.01, Percent Change: -0.90
|CME Group SOFR Futures Hit New Single-Day Trading Vo...|
|Fox Corp Unit Fox News Media's International Streami...|
|Research Alert: CFRA Maintains Hold Opinion On Share...|
|Market Chatter: National Labor Relations Board Repor...|
|Top Cryptocurrencies Retreat Alongside US Stocks; Bi...|